CHMP adopts positive opinion on Rasonque for metastatic pancreatic cancer
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 15 October 2026, recommending marketing authorisation for Rasonque, a daraxonrasib monotherapy for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. The product will be available as 100 mg and 150 mg film-coated tablets and is designated as an orphan medicine.
Primary source
EMA medicine page (CHMP opinion), October 15, 2026
Rasonque (Daraxonrasib): EMA CHMP opinion
Read the source: Rasonque (Daraxonrasib): EMA CHMP opinion ema.europa.eu
Machine-summarized from the source above; not independently reported. How we use automation